#PubSaludMurcia Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. https://t.co/TbH7PwWbfo
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in pret... https://t.co/0kf2LUMlYt #bmcinfectdis
#PubSaludMurcia Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in pre... https://t.co/XS22w0etlx
RT @fedemartinon: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants https://t.c…
Al fin publicado! Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus (SPAIN) https://t.co/hnKokntaxc #bmcinfectdis
RT @fedemartinon: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants https://t.c…
RT @fedemartinon: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants https://t.c…
RT @fedemartinon: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants https://t.c…
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants https://t.co/s6yhUZGFLe